Because there is a solid pharmacological rationale based on positive interactions between
long‐acting muscarinic receptor antagonists (LAMAs) and long‐acting β‐agonists (LABAs) …

Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

Bronchodilators are the cornerstone of symptomatic chronic obstructive pulmonary disease
(COPD) treatment. They are routinely recommended for symptom reduction, with a …

Background Chronic obstructive pulmonary disease (COPD) is a respiratory condition
causing accumulation of mucus in the airways, cough, and breathlessness; the disease is …

Background In chronic obstructive pulmonary disease (COPD) patients, combination
treatment with long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA) …

The natural disease course of chronic obstructive pulmonary disease (COPD) is often
punctuated by exacerbations: acute events of symptom worsening associated with …

Purpose Long-acting β2-agonists (LABAs) have demonstrated efficacy in patients with
COPD in clinical trials. The purpose of this study was to assess the comparative efficacy of …

Objective To compare the safety and effectiveness of long-acting β-antagonists (LABA), long-
acting antimuscarinic agents (LAMA) and inhaled corticosteroids (ICS) for managing chronic …

Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists,
are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD). The …

Introduction We performed a real-life retrospective analysis to assess the impact of long-
acting bronchodilator therapy and associated exposure to inhaled corticosteroids (ICS) on …